Latest news for CVC Capital Partners (OTC:CVCCF) Stock

CVC Capital Partners PLC is a alternative investment management focused on private equity, secondaries, Credit and Infrastructure. Private Equity platforms are focused on fundamentally sound, well-managed businesses, principally via control-oriented investments. Secondaries provides tailored liquidity solutions for third party general partners and limited partners. Credit Includes s (i) Performing Credit, focused on investing in U.S. and European senior secured loans and high yield bonds; and (ii) Private Credit, focused on investing in primary originated financing solutions for financial sponsors and corporates across the capital structure.

CVC CAPITAL PARTNERS PLC by CVC CAPITAL PARTNERS PLC

CVC Capital Partners PLC

Q3 2024 Outlook – Weyerhaeuser anticipates third quarter earnings will be approximately $10 million lower than the second quarter and Adjusted EBITDA will be approximately $30 million lower than the second quarter due to the timing and mix of real estate sales. The company now expects full year 2024 Adjusted EBITDA to be approximately $330 million, a $10 million increase from prior outlook, and continues to expect basis as a percentage of real estate sales to be 35 to 45 percent for the full year.
Q3 2024 Outlook – Weyerhaeuser anticipates third quarter earnings before special items and Adjusted EBITDA will be lower than the second quarter, excluding the effect of changes in average sales realizations for lumber and oriented strand board. For lumber, the company expects lower sales volumes, slightly lower log costs, and higher unit manufacturing costs. For oriented strand board, the company anticipates comparable sales volumes, slightly higher fiber costs, and moderately higher unit manufacturing costs. For engineered wood products, the company expects comparable sales volumes, lower raw material costs, and moderately lower sales realizations, primarily for plywood and medium density fiberboard. For distribution, the company anticipates slightly lower results compared to the second quarter.

News

Guidance

Weyerhaeuser Sees Q3 Earnings ~$10M Lower Than Q2, Adj. EBITDA Will Be ~$30M Lower Than Q2 Due To Timing And Mix Of Real Estate Sales; Sees FY24 Adj. EBITDA ~$330M, $10M Increase From Prior Outlook, Expect Basis As A Percentage Of Real Estate Sales To Be 35%-45%

Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 7.14 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $321.752 million which missed the analyst consensus estimate of $330.872 million by 2.76 percent. This is a 0.53 percent decrease over sales of $323.460 million the same period last year.

Earnings

Earnings Misses

Associated Banc Q2 2024 GAAP EPS $0.52, Inline, Sales $321.752M Miss $330.872M Estimate

DXCM

Dexcom Sees FY24 Revenue $4.00B-$4.05B vs $4.33B Est.

Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.26 by 23.08 percent. This is a 100 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $516.100 million which beat the analyst consensus estimate of $490.064 million by 5.31 percent. This is a 22.44 percent increase over sales of $421.500 million the same period last year.

Earnings Beats

UCTT

Ultra Clean Hldgs Q2 2024 Adj EPS $0.32 Beats $0.26 Estimate, Sales $516.100M Beat $490.064M Estimate

Jefferies analyst Randal Konik reiterates Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Underperform and maintains $220 price target.

Price Target

Reiteration

Analyst Ratings

LULU

Jefferies Reiterates Underperform on Lululemon Athletica, Maintains $220 Price Target

DexCom Sees Q3 2024 Revenue $975M-$1.00B vs $1.15B Est.

SSNC

SS&C Technologies Revises FY24 Adjusted Revenue Forecast From ~$5.694B – $5.854B To $5.706B – $5.866B (Est $5.78B),  Adjusted EPS From $4.93 – $5.17 To $4.98 – $5.22 (Est $5.11)

Horace Mann Educators Expects FY 2024 Core EPS Between $2.40 - $2.70, With Q2 Core EPS Of $0.18- $0.20; Confidence In Achieving 10% Return On Equity By 2025 Amid Profitability Restoration And Sales Growth

Buybacks

The Hartford Board Authorizes New $3B Buyback Program

Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 34.38 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $1.94 billion which missed the analyst consensus estimate of $1.95 billion by 0.62 percent. This is a 2.90 percent decrease over sales of $2.00 billion the same period last year.

Weyerhaeuser Q2 Adj $0.21, Inline, Sales $1.94B Miss $1.95B Estimate

Payable Sept. 26 To Shareholders Of Record As Of Aug. 27

Dividends

VOYA

Voya Financial Announces 12.5% Increase In Dividend From $0.40 To $0.45 Per Share For Q3 2024

Novo Nordisk A/S Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) experienced a notable decline on Thursday. This movement follows a significant announcement from <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">competitor Viking Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
What To Know: Viking Therapeutics announced the company has advanced its obesity candidate VK2735 into late-stage trials. This <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">advancement has intensified competition</a> in the GLP-1 market, which is currently led by Novo Nordisk and Eli Lilly corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Viking Therapeutics&#8217; report of promising results for its obesity drug, showing up to a 15% reduction in body weight over 13 weeks, has pressured Novo Nordisk. This development challenges Novo Nordisk's leading position in the obesity treatment market.
What Else: The options market for Novo Nordisk has shown a predominantly bearish sentiment recently. Out of eight detected trades, 62% were bearish, including three put options totaling $155,555 and five call options amounting to $255,360.
Novo Nordisk&#8217;s trading volume reached 1,568,565, with the stock nearing oversold conditions according to RSI indicators. The company's next earnings report is expected in 13 days. 
Analyst Opinions: Cantor Fitzgerald recently downgraded Novo Nordisk to &#8216;Overweight&#8217; but maintained a price target of $160.
NVO Price Action: Novo Nordisk shares were down by 2.88% at $127.86 according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png" alt="" class="wp-image-457886" style="width:425px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39966014/can-independent-bank-corp-run-higher-on-rising-earnings-estimates">Can Independent Bank Corp. Run Higher on Rising Earnings Estimates?</a></li>
</ul>
Photo via Shutterstock.

Health Care

After-Hours Center

Movers

VKTX

Novo Nordisk Shares Decline Amid Competitive Pressure

SS&C Sees FY24 Revenue $5.7B-$5.86B Vs $6.03B Estimate; Sees Adj. EPS $4.98-$5.22 Vs $5.64 Estimate

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. The company reported quarterly sales of $1.004 billion which missed the analyst consensus estimate of $1.036 billion by 3.13 percent. This is a 15.23 percent increase over sales of $871.300 million the same period last year.

DexCom Q2 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $1.004B Miss $1.036B Estimate

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) reported quarterly earnings of $3.97 per share which beat the analyst consensus estimate of $3.53 by 12.46 percent. The company reported quarterly sales of $384.55 million which beat the analyst consensus estimate of $372.57 million by 3.22 percent. This is a 30.02 percent increase over sales of $295.77 million the same period last year.

KNSL

Kinsale Cap Gr Q2 2024 Adj EPS $3.97 Beats $3.53 Estimate, Sales $384.55M Beat $372.57M Estimate

Data reviewed complies with standards that would be&nbsp;used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), a biotechnology company focused on developing and commercializing DNA medicines to&nbsp;help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that&nbsp;the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate&nbsp;for&nbsp;the treatment of Recurrent Respiratory Papillomatosis (RRP). The certification confirms that INOVIO's chemistry, manufacturing and controls (CMC) data and nonclinical results available to date comply with the scientific and technical standards that would be used for evaluating a European Marketing Authorization Application.

Biotech

General

Inovio Receives Advanced Therapy Medicinal Product Certificate From EMA For Quality And Non-Clinical Data For Lead Candidate INO-3107

Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $1.14 by 2.63 percent. The company reported quarterly sales of $462.164 million which beat the analyst consensus estimate of $461.600 million by 0.12 percent. This is a 12.02 percent increase over sales of $412.572 million the same period last year.

Universal Logistics Hldgs Q2 2024 GAAP EPS $1.17 Beats $1.14 Estimate, Sales $462.164M Beat $461.600M Estimate

Wolfe Research analyst Steve Fleishman downgrades NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Outperform to Peer Perform.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

CVC Capital Partners

News

Latest news for CVC Capital Partners (OTC:CVCCF) Stock